Mumbai : Ind-Swift Laboratories Limited, one of India’s leading pharma company, reported growth of 74% in net profit for the quarter ended September 30, 2010.
In the Quarter ended September 2010, the company’s Total Sales was up 8.33% at Rs. 212.83 crore as against Rs 196.46 crore in previous quarter.
EBIDTA stood at Rs 44.69 crore and operating margin of 20.99 % to sales as against Rs 35.86 crore in Q2FY10.
Profit After Tax (PAT) stood at Rs. 21.74 crore and net margin of 10.21% as against Rs 12.49 crore in Q2FY10.
In the six months ended September 2010, Total sales was up 12.57% at Rs. 412.88 crores as against Rs 366.78 crore in H1FY10.
EBIDTA was at Rs. 84.93 crores and operating margin of 20.94% to sales as aginst Rs 66.08 crore in H1FY10.
PAT was at Rs. 36.60 crores and net margin of 8.8% as against Rs 23.77 crores in H1FY10.
N.R.Munjal, Vice Chairman and Managing Director, said, “The Exports of the company during the Quarter rose by 11% from Rs. 86.27 crores to Rs. 95.02 crores. The improvement and growth in company’s performance is the result of better product mix, better realizations and improved margins.”
“Going forward, the company is focusing on the regulated markets of US, Australia and Japan in a big way for which it has already filed over 310 DMFs in various Countries, including that of US, Australia, NewZealand and Japan . We have also filed over 129 patent in various Countries”, added Munjal.